Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 14/20 | 0.45 |
| ▸ | CTSK | P43235 | 11/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 9/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077348 | 0.89 | CTSS (0.44) | CTSSCTSKHDAC4HDAC6HDAC1 | |
| Benzene SCHEMBL5955881 | 0.87 | HDAC4 (0.40) | CTSSCTSKHDAC4HDAC6HDAC1 | |
| SCHEMBL5955011 | 0.87 | CTSS (0.52) | CTSSCTSKCTSL | |
| SCHEMBL5955013 | 0.87 | CTSS (0.52) | CTSSCTSKCTSL | |
| SCHEMBL6076791 | 0.87 | CTSS (0.42) | CTSSCTSKCTSL | |
| SCHEMBL5955869 | 0.83 | CTSS (0.42) | CTSSCTSKHDAC4HDAC6HDAC1 | |
| SCHEMBL6081794 | 0.83 | CTSS (0.43) | CTSSCTSKHDAC6HDAC1HDAC8 | |
| SCHEMBL6081796 | 0.83 | CTSS (0.43) | CTSSCTSKHDAC6HDAC1HDAC8 | |
| SCHEMBL6077861 | 0.81 | CTSS (0.38) | CTSSCTSKCTSL | |
| SCHEMBL5955872 | 0.79 | HDAC6 (0.39) | CTSSCTSKHDAC4HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACUETICALS INC. | 2003-06-05 | — | — | US | claimed |
| US-7030116-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-18 | — | — | US | disclosed |
| WO-2004002491-A1 | MORPHOLINE AND TETRAHYDROPYRAN DRIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACUETICALS INC. | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CTSS 1/4885CTSK 8/4885HDAC4 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.